CINECA IRIS Institutional Research Information System

FIORAVANTI, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.641
AS - Asia 1.267
EU - Europa 1.264
SA - Sud America 154
Continente sconosciuto - Info sul continente non disponibili 97
AF - Africa 62
OC - Oceania 5
AN - Antartide 1
Totale 7.491
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.535
SG - Singapore 433
CN - Cina 332
IT - Italia 317
DE - Germania 278
HK - Hong Kong 198
SE - Svezia 172
BR - Brasile 127
VN - Vietnam 120
GB - Regno Unito 96
BG - Bulgaria 87
FR - Francia 83
CA - Canada 82
TR - Turchia 61
FI - Finlandia 52
AT - Austria 50
RU - Federazione Russa 42
IN - India 34
JP - Giappone 29
CI - Costa d'Avorio 25
UA - Ucraina 21
BE - Belgio 18
PL - Polonia 12
BD - Bangladesh 11
MX - Messico 10
NL - Olanda 10
SA - Arabia Saudita 9
AR - Argentina 8
ID - Indonesia 8
NG - Nigeria 8
EC - Ecuador 7
KR - Corea 7
MA - Marocco 7
ZA - Sudafrica 7
SN - Senegal 6
CO - Colombia 5
CZ - Repubblica Ceca 5
DK - Danimarca 5
AU - Australia 4
IQ - Iraq 4
LT - Lituania 4
PK - Pakistan 4
VE - Venezuela 4
CH - Svizzera 3
DO - Repubblica Dominicana 3
EG - Egitto 3
ES - Italia 3
JO - Giordania 3
AL - Albania 2
AZ - Azerbaigian 2
BB - Barbados 2
CL - Cile 2
CR - Costa Rica 2
HN - Honduras 2
KH - Cambogia 2
LB - Libano 2
NP - Nepal 2
RO - Romania 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
A1 - Anonimo 1
AM - Armenia 1
BJ - Benin 1
BN - Brunei Darussalam 1
DZ - Algeria 1
ET - Etiopia 1
EU - Europa 1
FJ - Figi 1
GD - Grenada 1
GS - Georgia del Sud e Isole Sandwich Australi 1
IE - Irlanda 1
IL - Israele 1
JM - Giamaica 1
MD - Moldavia 1
MY - Malesia 1
NI - Nicaragua 1
PE - Perù 1
SO - Somalia 1
SY - Repubblica araba siriana 1
UZ - Uzbekistan 1
Totale 7.396
Salva come PNG Salva come JPEG
Città #
Ashburn 478
Woodbridge 426
Ann Arbor 408
Fairfield 384
Houston 326
Singapore 228
Dallas 226
Chandler 222
Hong Kong 196
Santa Clara 186
Seattle 185
San Jose 180
Wilmington 170
Cambridge 138
Serra 132
New York 97
Sofia 87
Beijing 81
Shanghai 80
Los Angeles 76
Council Bluffs 57
Ottawa 48
Boardman 45
Vienna 45
Dong Ket 39
Des Moines 36
Izmir 36
Princeton 36
Lauterbourg 35
Medford 35
Lawrence 34
Dearborn 26
Falls Church 26
Abidjan 25
Frankfurt am Main 25
Tokyo 25
Columbus 23
The Dalles 23
Ho Chi Minh City 22
London 22
Munich 21
Buffalo 20
Rho 19
Boulder 18
Brussels 18
Istanbul 18
Jacksonville 18
Nanjing 18
Hanoi 17
San Diego 17
Denver 16
Florence 15
Montreal 15
Nürnberg 15
Redondo Beach 14
Milan 13
São Paulo 13
Turku 13
Bremen 12
Fuzhou 12
Phoenix 12
Pune 12
San Francisco 12
Nanchang 11
Orem 11
Seacroft 11
Pisa 10
Düsseldorf 9
Shenyang 9
Atlanta 8
Boston 8
Lagos 8
Ogden 8
Redwood City 8
Toronto 8
Marseille 7
Dakar 6
Helsinki 6
Lancaster 6
Seoul 6
Brooklyn 5
Changsha 5
Kunming 5
Norwalk 5
Warsaw 5
Caracas 4
Da Nang 4
Indiana 4
Memphis 4
Quito 4
Rio de Janeiro 4
Riyadh 4
Stockholm 4
Vancouver 4
Wroclaw 4
Amman 3
Auburn Hills 3
Bexley 3
Calgary 3
Chicago 3
Totale 5.547
Salva come PNG Salva come JPEG
Nome #
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients 549
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions 421
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 305
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. 271
VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 259
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 256
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 255
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 253
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 246
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients 244
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 228
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2 216
The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients. 211
Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies. 208
Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. 205
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 199
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 196
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine 193
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells 177
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 172
In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists 171
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. 171
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. 167
Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer 164
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells 158
Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer 158
Overexpression and functional relevance of somatostatin receptor-1, -2, and -5 in endometrium and endometriotic lesions 152
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer 152
Derivati a nucleo pirazolo[3,4-d]pirimidinico quali inibitori di proteine tirosina chinasi 149
Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1 149
The effect of osteogenic growth peptide (OGP) on proliferation and adhesion of HEMC-1 human endothelial cells 148
A new biometric tool for three-dimensional subcutaneous tumor scanning in mice. 147
Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. 124
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients 114
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. 113
null 101
null 89
Totale 7.491
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.832
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.832
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022463 0 41 20 14 76 65 16 21 25 26 22 137
2022/2023652 85 99 60 74 66 89 3 37 105 2 29 3
2023/2024244 21 18 27 5 26 64 9 20 5 6 14 29
2024/20251.173 3 44 5 90 138 142 65 50 150 147 110 229
2025/20261.679 105 127 211 111 147 108 227 60 92 91 371 29
2026/2027109 24 85 0 0 0 0 0 0 0 0 0 0
Totale 7.491